FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016110604> ?p ?o ?g. }

• W2016110604 endingPage "951" @default.
• W2016110604 startingPage "946" @default.
• W2016110604 abstract "Topoisomerase I inhibitors are new compounds of interest for cancer chemotherapy. We performed a study with GI147211, a new semisynthetic camptothecin analogue, to determine the absolute bioavailability of the drug given orally. Patients with a histologically confirmed diagnosis of a solid tumour refractory to standard forms of therapy were eligible for the study. GI147211 was given orally on day 1 and as a 30-min infusion daily on days 2-5. The treatment course was repeated every 3 weeks. In subsequent patient cohorts, the dose of the oral formulation was escalated from 1.5 mg m(-2) to 6.0 mg m(-2); the dose for i.v. administration was fixed at 1.2 mg m(-2). Plasma pharmacokinetics was performed on day 1 and 2 of the first course and on day 1 of the second course using a validated high-performance liquid chromatographic assay. Nineteen patients were entered into the study; one patient was not evaluable because the treatment course was stopped prematurely. Eighteen patients received a total of 47 treatment courses. The absolute bioavailability of GI147211 averaged 1.3 +/- 5.2%. Drug appeared quickly in plasma with a median Tmax at 0.5 h. Fasting or fed state had no significant influence on the bioavailability of GI147211. The terminal half-life after administration of oral GI147211 was 6.85 +/- 3.13 h, similar to the half-life after intravenous administration. The major toxicities were neutropenia and thrombocytopenia. Nadirs for neutropenia and thrombocytopenia occurred on day 8 and day 15 respectively. Other toxicities predominantly consisted of mild and infrequent nausea and vomiting, and fatigue. The oral administration of the drug is well tolerated. Oral administration of topoisomerase I inhibitor GI147211 results in a low bioavailability with relatively wide interpatient variation. The intravenous route of administration is advised for further development of this promising topoisomerase I inhibitor." @default.
• W2016110604 created "2016-06-24" @default.
• W2016110604 creator A5000418012 @default.
• W2016110604 creator A5011819733 @default.
• W2016110604 creator A5014515180 @default.
• W2016110604 creator A5016446106 @default.
• W2016110604 creator A5021449457 @default.
• W2016110604 creator A5042674500 @default.
• W2016110604 creator A5045167907 @default.
• W2016110604 creator A5057488349 @default.
• W2016110604 creator A5069473904 @default.
• W2016110604 creator A5086326839 @default.
• W2016110604 date "1997-10-01" @default.
• W2016110604 modified "2023-10-10" @default.
• W2016110604 title "The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor" @default.
• W2016110604 cites W1536538430 @default.
• W2016110604 cites W1595222265 @default.
• W2016110604 cites W1606440731 @default.
• W2016110604 cites W1626527928 @default.
• W2016110604 cites W1783332466 @default.
• W2016110604 cites W1952453258 @default.
• W2016110604 cites W1976750415 @default.
• W2016110604 cites W1979668375 @default.
• W2016110604 cites W1982075384 @default.
• W2016110604 cites W1995807442 @default.
• W2016110604 cites W2001837844 @default.
• W2016110604 cites W2011909208 @default.
• W2016110604 cites W2018061705 @default.
• W2016110604 cites W2032894521 @default.
• W2016110604 cites W203699266 @default.
• W2016110604 cites W2043703023 @default.
• W2016110604 cites W2057409012 @default.
• W2016110604 cites W2091111837 @default.
• W2016110604 cites W2092998745 @default.
• W2016110604 cites W2095355415 @default.
• W2016110604 cites W2102345056 @default.
• W2016110604 cites W2108018389 @default.
• W2016110604 cites W2127843578 @default.
• W2016110604 cites W2128297167 @default.
• W2016110604 cites W2133295671 @default.
• W2016110604 cites W2155735678 @default.
• W2016110604 cites W2156197215 @default.
• W2016110604 cites W2159921901 @default.
• W2016110604 cites W2255443552 @default.
• W2016110604 cites W2277082935 @default.
• W2016110604 cites W2397376517 @default.
• W2016110604 cites W2409654774 @default.
• W2016110604 cites W2419655738 @default.
• W2016110604 cites W37120966 @default.
• W2016110604 cites W38643767 @default.
• W2016110604 doi "https://doi.org/10.1038/bjc.1997.490" @default.
• W2016110604 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2228077" @default.
• W2016110604 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9328158" @default.
• W2016110604 hasPublicationYear "1997" @default.
• W2016110604 type Work @default.
• W2016110604 sameAs 2016110604 @default.
• W2016110604 citedByCount "26" @default.
• W2016110604 countsByYear W20161106042012 @default.
• W2016110604 countsByYear W20161106042017 @default.
• W2016110604 countsByYear W20161106042018 @default.
• W2016110604 countsByYear W20161106042022 @default.
• W2016110604 crossrefType "journal-article" @default.
• W2016110604 hasAuthorship W2016110604A5000418012 @default.
• W2016110604 hasAuthorship W2016110604A5011819733 @default.
• W2016110604 hasAuthorship W2016110604A5014515180 @default.
• W2016110604 hasAuthorship W2016110604A5016446106 @default.
• W2016110604 hasAuthorship W2016110604A5021449457 @default.
• W2016110604 hasAuthorship W2016110604A5042674500 @default.
• W2016110604 hasAuthorship W2016110604A5045167907 @default.
• W2016110604 hasAuthorship W2016110604A5057488349 @default.
• W2016110604 hasAuthorship W2016110604A5069473904 @default.
• W2016110604 hasAuthorship W2016110604A5086326839 @default.
• W2016110604 hasBestOaLocation W20161106042 @default.
• W2016110604 hasConcept C112705442 @default.
• W2016110604 hasConcept C121332964 @default.
• W2016110604 hasConcept C126322002 @default.
• W2016110604 hasConcept C142424586 @default.
• W2016110604 hasConcept C178790620 @default.
• W2016110604 hasConcept C181389837 @default.
• W2016110604 hasConcept C185592680 @default.
• W2016110604 hasConcept C2776694085 @default.
• W2016110604 hasConcept C2777056448 @default.
• W2016110604 hasConcept C2777063308 @default.
• W2016110604 hasConcept C2779682216 @default.
• W2016110604 hasConcept C71924100 @default.
• W2016110604 hasConcept C87355193 @default.
• W2016110604 hasConcept C90924648 @default.
• W2016110604 hasConcept C98274493 @default.
• W2016110604 hasConceptScore W2016110604C112705442 @default.
• W2016110604 hasConceptScore W2016110604C121332964 @default.
• W2016110604 hasConceptScore W2016110604C126322002 @default.
• W2016110604 hasConceptScore W2016110604C142424586 @default.
• W2016110604 hasConceptScore W2016110604C178790620 @default.
• W2016110604 hasConceptScore W2016110604C181389837 @default.
• W2016110604 hasConceptScore W2016110604C185592680 @default.
• W2016110604 hasConceptScore W2016110604C2776694085 @default.
• W2016110604 hasConceptScore W2016110604C2777056448 @default.
• W2016110604 hasConceptScore W2016110604C2777063308 @default.

• next